Ocular Therapeutix, Inc. (OCUL)
7.38
+0.18
(+2.50%)
USD |
NASDAQ |
Oct 15, 16:00
7.28
-0.10
(-1.36%)
After-Hours: 20:00
Ocular Therapeutix Research and Development Expense (Quarterly) : 54.14M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 54.14M |
| March 31, 2026 | 66.21M |
| December 31, 2025 | 50.80M |
| September 30, 2025 | 52.36M |
| June 30, 2025 | 51.08M |
| March 31, 2025 | 42.86M |
| December 31, 2024 | 40.99M |
| September 30, 2024 | 37.05M |
| June 30, 2024 | 28.86M |
| March 31, 2024 | 20.74M |
| December 31, 2023 | 16.20M |
| September 30, 2023 | 15.02M |
| June 30, 2023 | 15.09M |
| March 31, 2023 | 14.75M |
| December 31, 2022 | 13.54M |
| September 30, 2022 | 13.72M |
| June 30, 2022 | 13.10M |
| March 31, 2022 | 13.10M |
| December 31, 2021 | 12.58M |
| September 30, 2021 | 12.72M |
| June 30, 2021 | 13.86M |
| March 31, 2021 | 10.93M |
| December 31, 2020 | 7.624M |
| September 30, 2020 | 6.951M |
| June 30, 2020 | 8.021M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.098M |
| December 31, 2019 | 10.12M |
| September 30, 2019 | 10.24M |
| June 30, 2019 | 9.414M |
| March 31, 2019 | 11.32M |
| December 31, 2018 | 10.26M |
| September 30, 2018 | 9.685M |
| June 30, 2018 | 8.745M |
| March 31, 2018 | 8.227M |
| December 31, 2017 | 7.908M |
| September 30, 2017 | 7.436M |
| June 30, 2017 | 8.117M |
| March 31, 2017 | 6.729M |
| December 31, 2016 | 7.328M |
| September 30, 2016 | 5.686M |
| June 30, 2016 | 6.978M |
| March 31, 2016 | 7.005M |
| December 31, 2015 | 6.886M |
| September 30, 2015 | 8.198M |
| June 30, 2015 | 6.556M |
| March 31, 2015 | 4.546M |
| December 31, 2014 | 4.984M |
| September 30, 2014 | 4.482M |
| June 30, 2014 | 4.141M |
| March 31, 2014 | 4.865M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| EyePoint, Inc. | 83.61M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Eli Lilly & Co. | 3.819B |
| Corcept Therapeutics, Inc. | 53.89M |
| Veru, Inc. | 4.353M |